Bayer, J&J Sign Partner Deal With Portola for Xarelto Antidote

Bayer AG and Johnson & Johnson will work together with Portola Pharmaceuticals Inc. to quell doctors’ concerns about the lack of an antidote to their new blood-thinner Xarelto.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.